AR-15512: Results of Phase 3 Studies for Acoltremon Ophtalmic Solution 0.003%, a Novel TRPM8 Agonist | Alcon Science

Follow Us on LinkedIn

Alcon Science | United States

This page is available in English. Select below for other countries.

Select other country

Dry Eye

AR-15512: Results of Phase 3 Studies for Acoltremon Ophtalmic Solution 0.003%, a Novel TRPM8 Agonist

Sep 29, 2025

Watch the case study for Results of Phase 3 Studies for Acoltremon Ophtalmic Solution 0.003%, a Novel TRPM8 Agonist.

↑